Nature’s Sunshine Products, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $116.6 million (-9.1% year over year) and diluted EPS of $0.11. It usually reports 35–69 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 9, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Mar 10, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–69 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
117
-9.1%
|
2
-64.6%
|
0.11
-63.3%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
117
+1.9%
|
4
-33.7%
|
0.19
-32.1%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
123
+8.5%
|
5
+7.8%
|
0.29
+16.0%
|
|
Mar 10, 2026
69 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
124
+4.7%
|
4
+1379.4%
|
0.23
+1437.5%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
128
+12.0%
|
5
+22.7%
|
0.30
+30.4%
|
|
Jul 31, 2025
31 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
115
+3.8%
|
5
+295.3%
|
0.28
+300.0%
|
|
Mar 12, 2025
71 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
118
+8.5%
|
-0
-103.6%
|
-0.02
-103.7%
|
|
Nov 7, 2024
38 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NATR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- UT
- Headquarters
- Lehi, UT
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 275053
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.